Baxter Japan Eliminates Dose Limitations On Hemophilia Treatment
This article was originally published in PharmAsia News
Executive Summary
Baxter Japan announced April 17 that it had eliminated dose limitations to hemophilia drug Feiba from a points-to-consider treatment document. Before the change, Feiba was in principal limited to administration in patients within three consecutive days. A Ministry of Health, Labor and Welfare Insurance Bureau director's notice dated March 31 eliminated the three-day limitation. The change allows hemophilia patients a continuous administration of Feiba in situations such as surgery or heavy bleeding. (Click here for more - Japanese language